Big pharma stocks lost value overall in the fourth quarter of 2017 despite good performances from Asian companies and Kåre Schultz taking over at Teva.
Big pharma stocks lost just over $70bn in market value in Q4 2017, equivalent to slightly more than the market...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.
The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.
Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.
